951 related articles for article (PubMed ID: 30700611)
1. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.
Hulseberg CE; Fénéant L; Szymańska-de Wijs KM; Kessler NP; Nelson EA; Shoemaker CJ; Schmaljohn CS; Polyak SJ; White JM
J Virol; 2019 Apr; 93(8):. PubMed ID: 30700611
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs.
Herring S; Oda JM; Wagoner J; Kirchmeier D; O'Connor A; Nelson EA; Huang Q; Liang Y; DeWald LE; Johansen LM; Glass PJ; Olinger GG; Ianevski A; Aittokallio T; Paine MF; Fink SL; White JM; Polyak SJ
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468464
[TBL] [Abstract][Full Text] [Related]
3. Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis.
Oppliger J; Torriani G; Herrador A; Kunz S
J Virol; 2016 Jul; 90(14):6412-6429. PubMed ID: 27147735
[TBL] [Abstract][Full Text] [Related]
4. Lamp1 Increases the Efficiency of Lassa Virus Infection by Promoting Fusion in Less Acidic Endosomal Compartments.
Hulseberg CE; Fénéant L; Szymańska KM; White JM
mBio; 2018 Jan; 9(1):. PubMed ID: 29295909
[TBL] [Abstract][Full Text] [Related]
5. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.
Wang P; Liu Y; Zhang G; Wang S; Guo J; Cao J; Jia X; Zhang L; Xiao G; Wang W
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899092
[No Abstract] [Full Text] [Related]
6. Identification of a clinical compound losmapimod that blocks Lassa virus entry.
Zhang X; Yan F; Tang K; Chen Q; Guo J; Zhu W; He S; Banadyga L; Qiu X; Guo Y
Antiviral Res; 2019 Jul; 167():68-77. PubMed ID: 30953674
[TBL] [Abstract][Full Text] [Related]
7. The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein.
Zhang X; Tang K; Guo Y
Antiviral Res; 2020 Feb; 174():104701. PubMed ID: 31877348
[TBL] [Abstract][Full Text] [Related]
8. CP100356 Hydrochloride, a P-Glycoprotein Inhibitor, Inhibits Lassa Virus Entry: Implication of a Candidate Pan-Mammarenavirus Entry Inhibitor.
Takenaga T; Zhang Z; Muramoto Y; Fehling SK; Hirabayashi A; Takamatsu Y; Kajikawa J; Miyamoto S; Nakano M; Urata S; Groseth A; Strecker T; Noda T
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578344
[TBL] [Abstract][Full Text] [Related]
9. Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.
Torriani G; Trofimenko E; Mayor J; Fedeli C; Moreno H; Michel S; Heulot M; Chevalier N; Zimmer G; Shrestha N; Plattet P; Engler O; Rothenberger S; Widmann C; Kunz S
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626681
[TBL] [Abstract][Full Text] [Related]
10. Acidic pH Triggers Lipid Mixing Mediated by Lassa Virus GP.
Bulow U; Govindan R; Munro JB
Viruses; 2020 Jul; 12(7):. PubMed ID: 32630688
[TBL] [Abstract][Full Text] [Related]
11. Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein.
Shankar S; Whitby LR; Casquilho-Gray HE; York J; Boger DL; Nunberg JH
J Virol; 2016 Aug; 90(15):6799-807. PubMed ID: 27194767
[TBL] [Abstract][Full Text] [Related]
12. Novel Small Molecule Entry Inhibitors of Ebola Virus.
Basu A; Mills DM; Mitchell D; Ndungo E; Williams JD; Herbert AS; Dye JM; Moir DT; Chandran K; Patterson JL; Rong L; Bowlin TL
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S425-34. PubMed ID: 26206510
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
[TBL] [Abstract][Full Text] [Related]
14. A novel
Odongo L; Habtegebrael BH; Kiessling V; White JM; Tamm LK
Microbiol Spectr; 2023 Sep; 11(5):e0190823. PubMed ID: 37728342
[TBL] [Abstract][Full Text] [Related]
15. Screening and identification of Lassa virus endonuclease-targeting inhibitors from a fragment-based drug discovery library.
Lan X; Zhang Y; Jia X; Dong S; Liu Y; Zhang M; Guo J; Cao J; Guo Y; Xiao G; Wang W
Antiviral Res; 2022 Jan; 197():105230. PubMed ID: 34965446
[TBL] [Abstract][Full Text] [Related]
16. Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems.
Welch SR; Guerrero LW; Chakrabarti AK; McMullan LK; Flint M; Bluemling GR; Painter GR; Nichol ST; Spiropoulou CF; Albariño CG
Antiviral Res; 2016 Dec; 136():9-18. PubMed ID: 27771389
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection.
Zhang X; Ao Z; Bello A; Ran X; Liu S; Wigle J; Kobinger G; Yao X
Antiviral Res; 2016 Mar; 127():20-31. PubMed ID: 26778707
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Interactome Analysis Reveals that STT3B Is Required for N-Glycosylation of Lassa Virus Glycoprotein.
Zhu S; Wan W; Zhang Y; Shang W; Pan X; Zhang LK; Xiao G
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511384
[TBL] [Abstract][Full Text] [Related]
19. Emerging intracellular receptors for hemorrhagic fever viruses.
Jae LT; Brummelkamp TR
Trends Microbiol; 2015 Jul; 23(7):392-400. PubMed ID: 26004032
[TBL] [Abstract][Full Text] [Related]
20. Immunobiology of Ebola and Lassa virus infections.
Prescott JB; Marzi A; Safronetz D; Robertson SJ; Feldmann H; Best SM
Nat Rev Immunol; 2017 Mar; 17(3):195-207. PubMed ID: 28111475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
